Hikma Pharmaceuticals Plc (LON:HIK) had its price objective dropped by equities researchers at Stifel Nicolaus from GBX 1,320 ($17.36) to GBX 1,000 ($13.15) in a research report issued on Thursday. The firm presently has a “hold” rating on the stock. Stifel Nicolaus’ price objective would indicate a potential upside of 1.89% from the company’s current price.

Other equities analysts also recently issued research reports about the stock. Numis Securities Ltd reaffirmed an “add” rating and set a GBX 1,560 ($20.52) price target on shares of Hikma Pharmaceuticals Plc in a report on Thursday, August 17th. Morgan Stanley downgraded shares of Hikma Pharmaceuticals Plc to an “equal weight” rating and lowered their target price for the stock from GBX 1,600 ($21.04) to GBX 1,350 ($17.76) in a report on Monday, August 21st. Jefferies Group LLC reissued a “hold” rating and issued a GBX 1,045 ($13.74) target price on shares of Hikma Pharmaceuticals Plc in a report on Thursday. Peel Hunt reissued a “hold” rating and issued a GBX 1,390 ($18.28) target price on shares of Hikma Pharmaceuticals Plc in a report on Tuesday, October 31st. Finally, Citigroup Inc. reissued a “neutral” rating and issued a GBX 1,350 ($17.76) target price on shares of Hikma Pharmaceuticals Plc in a report on Thursday, August 24th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and three have given a buy rating to the company. Hikma Pharmaceuticals Plc has an average rating of “Hold” and an average price target of GBX 1,321.91 ($17.39).

Shares of Hikma Pharmaceuticals Plc (LON:HIK) traded down GBX 17.04 ($0.22) during trading hours on Thursday, reaching GBX 981.46 ($12.91). 2,310,000 shares of the company’s stock traded hands, compared to its average volume of 823,245. Hikma Pharmaceuticals Plc has a twelve month low of GBX 934 ($12.28) and a twelve month high of GBX 2,346 ($30.86).

TRADEMARK VIOLATION NOTICE: This news story was originally published by Watch List News and is the property of of Watch List News. If you are reading this news story on another domain, it was stolen and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://www.watchlistnews.com/stifel-nicolaus-lowers-hikma-pharmaceuticals-plc-hik-price-target-to-gbx-1000/1696702.html.

Hikma Pharmaceuticals Plc Company Profile

Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company’s segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products across the Middle East and North Africa (MENA) region and other markets.

Analyst Recommendations for Hikma Pharmaceuticals Plc (LON:HIK)

Receive News & Ratings for Hikma Pharmaceuticals Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals Plc and related companies with Analyst Ratings Network's FREE daily email newsletter.